Diana Sergeyevna Novikova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diana Sergeyevna Novikova has a total of 276 co-authors. Here are the top co-authors by number of shared publications:
E L Nasonov
38 shared publications- Tatiana Valentinovna Popkova
Nasonova Research Institute of Rheumatology
19 shared publications T V Popkova
16 shared publicationsE S Mach
15 shared publicationsA A Novikov
12 shared publicationsT. V. Popkova
V.A. Nasonova Research Institute of Rheumatology
11 shared publications
Latest Publications
- Open Access
- 4 October 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (9) , 6958
Clinical, demographic, and phenotypic characteristics and management of patients with recurrent pericarditis in real-world practice. Results of the retrospective branch of the international RUDRA registry
Aim . To identify the clinical and demographic profile, disease course, and management of patients with recurrent pericarditis (RP) based on data from the retrospective branch of the RUDRA registry, and to analyze specific patient subgroups. Material and methods . RUDRA (ClinicalTrials.gov: NCT06517966) is an international, multicenter, non-interventional real-world practice registry organized by the Eurasian Association of Internal Medicine, involving 20 centers across 14 regions of the Russian Federation and the Republic of Kazakhstan. The retrospective cohort included men and women aged 18 years and older with a verified diagnosis of RP established within the previous 10 years. Patient enrollment was conducted from September 30, 2024, to July 31, 2025. Statistical data analysis was performed using IBM SPSS Statistics 25. Results. The retrospective branch of the RUDRA registry included 120 patients. Idiopathic recurrent pericarditis (IRP) was verified in 33,3% (n=40), while RP of established etiology was identified in 66,7% (n=80). The median age was 63,0 [50,0;73,0] years; 55,0% were female. Patients with IRP were characterized by a significantly larger volume of pericardial effusion (386 [200;600] vs 200 [100;500] ml; p=0,008), a higher frequency of pericardial strands, clots, and adhesions (40,0% vs 11,4%; p=0,002), as well as higher rates of hospitalization (43,8% vs 9,1%; pConclusion . The retrospective branch of the RUDRA registry has provided the first systematized data on real-world clinical practice in the management of patients with RP in the Russian Federation and the Republic of Kazakhstan. IRP was characterized by a more severe clinical course, a higher social burden, and predominantly medication-induced remission. A significant gap between clinical guidelines and real-world practice was identified, specifically regarding the insufficient use of colchicine in RP of known etiology and the critically low availability of interleukin-1 inhibitors.
- 4 October 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (9) , 6958
Open AccessClinical, demographic, and phenotypic characteristics and management of patients with recurrent pericarditis in real-world practice. Results of the retrospective branch of the international RUDRA registry
Aim . To identify the clinical and demographic profile, disease course, and management of patients with recurrent pericarditis (RP) based on data from the retrospective branch of the RUDRA registry, and to analyze specific patient subgroups. Material and methods . RUDRA (ClinicalTrials.gov: NCT06517966) is an international, multicenter, non-interventional real-world practice registry organized by the Eurasian Association of Internal Medicine, involving 20 centers across 14 regions of the Russian Federation and the Republic of Kazakhstan. The retrospective cohort included men and women aged 18 years and older with a verified diagnosis of RP established within the previous 10 years. Patient enrollment was conducted from September 30, 2024, to July 31, 2025. Statistical data analysis was performed using IBM SPSS Statistics 25. Results. The retrospective branch of the RUDRA registry included 120 patients. Idiopathic recurrent pericarditis (IRP) was verified in 33,3% (n=40), while RP of established etiology was identified in 66,7% (n=80). The median age was 63,0 [50,0;73,0] years; 55,0% were female. Patients with IRP were characterized by a significantly larger volume of pericardial effusion (386 [200;600] vs 200 [100;500] ml; p=0,008), a higher frequency of pericardial strands, clots, and adhesions (40,0% vs 11,4%; p=0,002), as well as higher rates of hospitalization (43,8% vs 9,1%; pConclusion . The retrospective branch of the RUDRA registry has provided the first systematized data on real-world clinical practice in the management of patients with RP in the Russian Federation and the Republic of Kazakhstan. IRP was characterized by a more severe clinical course, a higher social burden, and predominantly medication-induced remission. A significant gap between clinical guidelines and real-world practice was identified, specifically regarding the insufficient use of colchicine in RP of known etiology and the critically low availability of interleukin-1 inhibitors.
- Open Access
- 6 September 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (4) , 411–417
Calcification of coronary arteries in patients with calcium pyrophosphate crystal deposition disease and knee osteoarthritis
The frequency of vascular calcification in patients with osteoarthritis (OA) and calcium pyrophosphate crystal deposition disease (CPPD) has not yet been studied, and the role of calcium crystals (basic and pyrophosphates) in the development of calcification is also unknown.Objective. Determine the presence and degree of calcification of the coronary vessels in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis of the knee joints with no clinical signs of cardiovascular diseases.Materials and methods. One-stage, single-center study, performed by the “case – control” method. The main group – 20 patients with CPPD, the comparison group – 20 patients with OA of the knee joints. Inclusion criteria: age from 18 to 65 years; absence of clinical signs of cardiovascular disease at the time of examination and indications of a history of cardiovascular accidents. Exclusion criteria: unsigned informed consent; pregnancy; breastfeeding; other rheumatic disease; cancer; high and very high cardiovascular risk on the SCORE scale. The survey included an assessment of anthropometric data, blood pressure (BP), lipid profile, serum levels of glucose, creatinine, uric acid, C-reactive protein, vitamin D, osteoprotegerin, parathyroid hormone, and the levels of magnesium, phosphorus, and total calcium were studied. All patients underwent multispiral computed tomography with determination of calcium count and the number of affected arteries. To calculate the coronary score, the A.S. Agatston et al.Results and discussion. Most of the parameters in the compared groups did not differ. When assessing the calcification of the coronary arteries according to the A.S. Agatston et al. 9 (45%) patients with CPPD and 8 (40%) patients with OA had a coronary calcium score >1. Quantitative indicators of calcium score can correspond to coronary artery stenosis ≥20% in 8 (40%) patients with CPPD and in 5 (25%) patients with OA according to J.A. Rumberger et al. The serum level of osteoprotegerin was significantly higher in patients with a calcium score ≥27 according to J.A. Rumberger et al. (p=0.04). Calcification was detected in 9 (56%) of 16 patients with serum vitamin D levels 30 ng/ml.Conclusions. In patients with an initially low cardiovascular risk, the probability of a combination of chondrocalcinosis and cardiovascular calcification is 45%, in OA it is 40%. The risk factors for coronary calcification in patients with CPPD and OA should be studied further.
- 6 September 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (4) , 411–417
Open AccessCalcification of coronary arteries in patients with calcium pyrophosphate crystal deposition disease and knee osteoarthritis
The frequency of vascular calcification in patients with osteoarthritis (OA) and calcium pyrophosphate crystal deposition disease (CPPD) has not yet been studied, and the role of calcium crystals (basic and pyrophosphates) in the development of calcification is also unknown.Objective. Determine the presence and degree of calcification of the coronary vessels in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis of the knee joints with no clinical signs of cardiovascular diseases.Materials and methods. One-stage, single-center study, performed by the “case – control” method. The main group – 20 patients with CPPD, the comparison group – 20 patients with OA of the knee joints. Inclusion criteria: age from 18 to 65 years; absence of clinical signs of cardiovascular disease at the time of examination and indications of a history of cardiovascular accidents. Exclusion criteria: unsigned informed consent; pregnancy; breastfeeding; other rheumatic disease; cancer; high and very high cardiovascular risk on the SCORE scale. The survey included an assessment of anthropometric data, blood pressure (BP), lipid profile, serum levels of glucose, creatinine, uric acid, C-reactive protein, vitamin D, osteoprotegerin, parathyroid hormone, and the levels of magnesium, phosphorus, and total calcium were studied. All patients underwent multispiral computed tomography with determination of calcium count and the number of affected arteries. To calculate the coronary score, the A.S. Agatston et al.Results and discussion. Most of the parameters in the compared groups did not differ. When assessing the calcification of the coronary arteries according to the A.S. Agatston et al. 9 (45%) patients with CPPD and 8 (40%) patients with OA had a coronary calcium score >1. Quantitative indicators of calcium score can correspond to coronary artery stenosis ≥20% in 8 (40%) patients with CPPD and in 5 (25%) patients with OA according to J.A. Rumberger et al. The serum level of osteoprotegerin was significantly higher in patients with a calcium score ≥27 according to J.A. Rumberger et al. (p=0.04). Calcification was detected in 9 (56%) of 16 patients with serum vitamin D levels 30 ng/ml.Conclusions. In patients with an initially low cardiovascular risk, the probability of a combination of chondrocalcinosis and cardiovascular calcification is 45%, in OA it is 40%. The risk factors for coronary calcification in patients with CPPD and OA should be studied further.
- Open Access
- 3 January 2020
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 15 (6) , 820-830-830
Chronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs
Chronic autoimmune inflammation is one of the leading risk factors for the development of chronic heart failure (CHF) in rheumatoid arthritis (RA). The purpose of the review is to analyze the results of investigations on the effects of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biological disease-modifying anti-rheumatic drugs (bDMARDs), and targeted csDMARDs on cardiac function and the risk of developing CHF in patients with RA. Methotrexate may reduce the CHF risk and have a positive effect on the course of this condition in patients with RA. Despite the data on the presence of leflunomide effects that impede myocardial remodeling, there is no evidence of the role of the drug in the prevention of CHF in RA patients. Hydroxychloroquine may contribute to the prevention of CHF, but the risk of developing severe cardiotoxicity should be considered when taking the drug for a long time. Most studies have not revealed the negative effect of tumor necrosis factor inhibitors on the prevalence and incidence of new cases of CHF in RA patients, and an improvement in the structure and function of the heart during therapy has been shown. Inhibitors of interleukin (IL) -1, inhibitors of IL-6, inhibitors of T-cell co-stimulation, anti-B-cell therapy, targeted csDMARDs do not increase the risk of CHF and may have cardioprotective effects, including slowing the progression of left ventricle myocardial dysfunction. Due to the high risk of CHF and CHF-associated mortality in RA patients, early diagnosis of cardiac dysfunction, development of a prevention and treatment strategies are needed, including high-quality prospective studies to assess the effect of anti-rheumatic therapy on myocardial function, risk of developing and decompensation of CHF in RA patients. It is possible that some drugs may possess protective effects on cardiomyocytes so they could become the first-line drugs in patients with CHF or the risk of its development.
- 3 January 2020
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 15 (6) , 820-830-830
Open AccessChronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs
Chronic autoimmune inflammation is one of the leading risk factors for the development of chronic heart failure (CHF) in rheumatoid arthritis (RA). The purpose of the review is to analyze the results of investigations on the effects of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biological disease-modifying anti-rheumatic drugs (bDMARDs), and targeted csDMARDs on cardiac function and the risk of developing CHF in patients with RA. Methotrexate may reduce the CHF risk and have a positive effect on the course of this condition in patients with RA. Despite the data on the presence of leflunomide effects that impede myocardial remodeling, there is no evidence of the role of the drug in the prevention of CHF in RA patients. Hydroxychloroquine may contribute to the prevention of CHF, but the risk of developing severe cardiotoxicity should be considered when taking the drug for a long time. Most studies have not revealed the negative effect of tumor necrosis factor inhibitors on the prevalence and incidence of new cases of CHF in RA patients, and an improvement in the structure and function of the heart during therapy has been shown. Inhibitors of interleukin (IL) -1, inhibitors of IL-6, inhibitors of T-cell co-stimulation, anti-B-cell therapy, targeted csDMARDs do not increase the risk of CHF and may have cardioprotective effects, including slowing the progression of left ventricle myocardial dysfunction. Due to the high risk of CHF and CHF-associated mortality in RA patients, early diagnosis of cardiac dysfunction, development of a prevention and treatment strategies are needed, including high-quality prospective studies to assess the effect of anti-rheumatic therapy on myocardial function, risk of developing and decompensation of CHF in RA patients. It is possible that some drugs may possess protective effects on cardiomyocytes so they could become the first-line drugs in patients with CHF or the risk of its development.
- Open Access
- 13 November 2019
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 47 (5) , 400-409
The course of chronic heart failure in patients with early rheumatoid arthritis on the anti-rheumatic therapy
Objective: To evaluate the effect of the “treat to target” anti-rheumatic therapy on the course of chronic heart failure (CHF) in patients with early rheumatoid arthritis (RA). Materials and methods: The study included 22 patients (17, or 77% female) with CHF with valid diagnosis of RA (ACR/EULAR criteria, 2010), median (Me) age of 60 years, and median disease duration of 7 months. Ten patients (45%) were seropositive for IgM rheumatoid factor and 22 (100%) had antibodies to cyclic citrulline peptide. Their median (1st; 3rd quartiles) DAS28 was 5.6 [4.8; 6.5]. The diagnosis of CHF was confirmed in accordance with the guidelines on the diagnosis and treatment of CHF by the Russian Society of Specialists in Heart Failure (2013). NT-proBNP levels were measured by electrochemiluminescence (Elecsys proBNP II, Roche Diagnostics, Switzerland). All patients were started on subcutaneous methotrexate (MT) with rapid dose titration to 30 mg weekly. If the MT was insufficiently effective, a biological disease-modifying antirheumatic drug (bDMARD) was added to the therapy after 3 months, mainly a TNF-alpha inhibitor. After 18 months, 10 (45%) patients were in remission and had low disease activity, 6 (60%) patients underwent MT therapy in combination with bDMARDs. Results: At baseline, 21 (95%) patients were diagnosed with CHF with preserved ejection fraction and one patient had CHF with reduced ejection fraction. After 18 months there was an improvement of clinical symptoms, echocardiographic parameters (reduction of the left atrium diameter and the left atrium end-systolic volume index, IVRT, E'LV), and diastolic function of the left ventricle (LV). No episodes of acute CHF deterioration were registered. LV diastolic function normalized in 7 (32%) patients who reached the target level of blood pressure, remission (n=5) and low disease activity (n=2), mainly under the treatment with MT and bDMARDs. In patients with RA and CHF, the NT-proBNP levels decreased from 192.2 [151.4; 266.4] to 114.0 [90.4; 163.4] pg/ml (pConclusion: In the patients with early RA and CHF anti-rheumatic therapy improves the clinical course of CHF, LV diastolic function and reduces NT-proBNP levels.
- 13 November 2019
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 47 (5) , 400-409
Open AccessThe course of chronic heart failure in patients with early rheumatoid arthritis on the anti-rheumatic therapy
Objective: To evaluate the effect of the “treat to target” anti-rheumatic therapy on the course of chronic heart failure (CHF) in patients with early rheumatoid arthritis (RA). Materials and methods: The study included 22 patients (17, or 77% female) with CHF with valid diagnosis of RA (ACR/EULAR criteria, 2010), median (Me) age of 60 years, and median disease duration of 7 months. Ten patients (45%) were seropositive for IgM rheumatoid factor and 22 (100%) had antibodies to cyclic citrulline peptide. Their median (1st; 3rd quartiles) DAS28 was 5.6 [4.8; 6.5]. The diagnosis of CHF was confirmed in accordance with the guidelines on the diagnosis and treatment of CHF by the Russian Society of Specialists in Heart Failure (2013). NT-proBNP levels were measured by electrochemiluminescence (Elecsys proBNP II, Roche Diagnostics, Switzerland). All patients were started on subcutaneous methotrexate (MT) with rapid dose titration to 30 mg weekly. If the MT was insufficiently effective, a biological disease-modifying antirheumatic drug (bDMARD) was added to the therapy after 3 months, mainly a TNF-alpha inhibitor. After 18 months, 10 (45%) patients were in remission and had low disease activity, 6 (60%) patients underwent MT therapy in combination with bDMARDs. Results: At baseline, 21 (95%) patients were diagnosed with CHF with preserved ejection fraction and one patient had CHF with reduced ejection fraction. After 18 months there was an improvement of clinical symptoms, echocardiographic parameters (reduction of the left atrium diameter and the left atrium end-systolic volume index, IVRT, E'LV), and diastolic function of the left ventricle (LV). No episodes of acute CHF deterioration were registered. LV diastolic function normalized in 7 (32%) patients who reached the target level of blood pressure, remission (n=5) and low disease activity (n=2), mainly under the treatment with MT and bDMARDs. In patients with RA and CHF, the NT-proBNP levels decreased from 192.2 [151.4; 266.4] to 114.0 [90.4; 163.4] pg/ml (pConclusion: In the patients with early RA and CHF anti-rheumatic therapy improves the clinical course of CHF, LV diastolic function and reduces NT-proBNP levels.
- 3 May 2019
- Published by Springer Nature in Rheumatology International
- Vol. 39 (7) , 1181-1189
Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib
The increase in cardiovascular risk in patients with rheumatoid arthritis (RA) compared with the general population is due to the combined effect of traditional risk factors for cardiovascular diseases, metabolic disorders, systemic inflammation, and side effects of antirheumatic drugs. Tofacitinib (TOFA) is an oral reversible inhibitor of janus kinases for the treatment of RA with proven efficacy and good tolerability, but its effects on body weight and metabolic profile need to be clarified. We investigated the effects of TOFA on body mass index (BMI) and visceral adiposity index (VAI) in RA patients. Thirty-one consecutive patients with active RA and starting new treatment with TOFA were included in a prospective 1 year follow-up observational study of cardiovascular effects of TOFA treatment. Weight, height, waist circumference, BMI, blood pressure, lipid profile, fasting glucose and VAI were measured at baseline and 12 months of treatment. Median weight gain was 3 kg (4.2%) after 1 year of TOFA. 23 (74%) patients suffered from a weight gain, and 6 (26%) out of them from a weight increment of 10% or more. Patients with lower BMI (p = 0.024) and higher baseline DAS28 [ESR] (p = 0.017) have the risk of an increase in BMI > 5% during TOFA treatment in a multivariate analysis. A decrease in VAI after 12 months was recorded. Weight increment and improvement of VAI are frequent on TOFA treatment. BMI dynamics associated with higher disease activity at baseline and lower baseline BMI.
- 3 May 2019
- Published by Springer Nature in Rheumatology International
- Vol. 39 (7) , 1181-1189
Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib
The increase in cardiovascular risk in patients with rheumatoid arthritis (RA) compared with the general population is due to the combined effect of traditional risk factors for cardiovascular diseases, metabolic disorders, systemic inflammation, and side effects of antirheumatic drugs. Tofacitinib (TOFA) is an oral reversible inhibitor of janus kinases for the treatment of RA with proven efficacy and good tolerability, but its effects on body weight and metabolic profile need to be clarified. We investigated the effects of TOFA on body mass index (BMI) and visceral adiposity index (VAI) in RA patients. Thirty-one consecutive patients with active RA and starting new treatment with TOFA were included in a prospective 1 year follow-up observational study of cardiovascular effects of TOFA treatment. Weight, height, waist circumference, BMI, blood pressure, lipid profile, fasting glucose and VAI were measured at baseline and 12 months of treatment. Median weight gain was 3 kg (4.2%) after 1 year of TOFA. 23 (74%) patients suffered from a weight gain, and 6 (26%) out of them from a weight increment of 10% or more. Patients with lower BMI (p = 0.024) and higher baseline DAS28 [ESR] (p = 0.017) have the risk of an increase in BMI > 5% during TOFA treatment in a multivariate analysis. A decrease in VAI after 12 months was recorded. Weight increment and improvement of VAI are frequent on TOFA treatment. BMI dynamics associated with higher disease activity at baseline and lower baseline BMI.
- Open Access
- 4 November 2018
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 14 (5) , 703-710-710
Chronic Heart Failure in Rheumatoid Arthritis Patients (Part I): Prevalence, Etiology and Pathogenesis
Rheumatoid arthritis (RA) is a disease with a high cardiovascular risk, which is caused, in particular, by an increased incidence of chronic heart failure (CHF). Analysis of the results of the main studies on the prevalence of CHF, the features of the etiology and pathogenesis of myocardial dysfunction in RA was the purpose of the review. According to the registers, population and epidemiological studies, the risk of CHF and CHF-associated mortality in RA patients is 1.5-2.5 times higher than in the general population. In most of the studies only clinically manifested congestive heart failure (HF) was considered, so the actual prevalence of CHF may be significantly underestimated. An increase in the risk of CHF was noted immediately after the debut of RA, with the prevalence of HF with preserved systolic function of the left ventricle, which indicates the important role of diastole disturbance in the pathogenesis of myocardial dysfunction. Chronic systemic autoimmune inflammation contributes to the development of CHF in RA patients, in addition to coronary heart disease, traditional risk factors (TRFs) of cardiovascular diseases (CVD). Inflammation plays a leading role in the development of CHF through various mechanisms including direct damage to the myocardium and coronary arteries (myocarditis, coronary vasculitis, microcirculatory disorders), aggravation of the severity of TRFs of CVD, accelerated progression of ischemic heart disease, endothelial dysfunction, increased vascular wall stiffness, cardiac and vascular remodeling. Early diagnosis of CHF and timely measures that can slow its progression is needed due to the high risk of CHF and CHF-associated mortality in RA patients, especially in patients with risk factors for CHF.
- 4 November 2018
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 14 (5) , 703-710-710
Open AccessChronic Heart Failure in Rheumatoid Arthritis Patients (Part I): Prevalence, Etiology and Pathogenesis
Rheumatoid arthritis (RA) is a disease with a high cardiovascular risk, which is caused, in particular, by an increased incidence of chronic heart failure (CHF). Analysis of the results of the main studies on the prevalence of CHF, the features of the etiology and pathogenesis of myocardial dysfunction in RA was the purpose of the review. According to the registers, population and epidemiological studies, the risk of CHF and CHF-associated mortality in RA patients is 1.5-2.5 times higher than in the general population. In most of the studies only clinically manifested congestive heart failure (HF) was considered, so the actual prevalence of CHF may be significantly underestimated. An increase in the risk of CHF was noted immediately after the debut of RA, with the prevalence of HF with preserved systolic function of the left ventricle, which indicates the important role of diastole disturbance in the pathogenesis of myocardial dysfunction. Chronic systemic autoimmune inflammation contributes to the development of CHF in RA patients, in addition to coronary heart disease, traditional risk factors (TRFs) of cardiovascular diseases (CVD). Inflammation plays a leading role in the development of CHF through various mechanisms including direct damage to the myocardium and coronary arteries (myocarditis, coronary vasculitis, microcirculatory disorders), aggravation of the severity of TRFs of CVD, accelerated progression of ischemic heart disease, endothelial dysfunction, increased vascular wall stiffness, cardiac and vascular remodeling. Early diagnosis of CHF and timely measures that can slow its progression is needed due to the high risk of CHF and CHF-associated mortality in RA patients, especially in patients with risk factors for CHF.
- 11 May 2018
- Published by Springer Nature in Rheumatology International
- Vol. 38 (7) , 1217-1224
Dynamic of changes in coronary artery calcification in early rheumatoid arthritis patients over 18 months
The coronary artery calcification (CAC) progression may be useful noninvasive predictor of future cardiovascular events (CVE). The progression rate of CAC in patients with early rheumatoid arthritis (RA) is poorly understood. To assess the dynamic of CAC scores in early RA patients for 18 months, 74 RA adult patients (ACR/EULAR criteria, 2010, duration ≤ 12 months, with moderate/high RA activity, without prior administration of disease-modifying anti-rheumatic drugs or glucocorticoids) were enrolled within the framework of the observational study: women 73%, median age 56 years, median RA duration 6 months, median DAS28[ESR] 5.4. Most of the patients had multiple Traditional Risk Factors (TRFs) of Cardiovascular Disease (CVD). All patients at baseline and after 18 months underwent 32-row scanning for CAC scoring. In patients younger than 45 years (n = 16) any CAC was not detected during 18 months. Among patients older than 45 years four new events of CAC were detected. Among patients older than 45 years with baseline CAC (n = 34) increase in CAC scores was detected in 82% cases. Among them, Δ Agatston Score exceeded the median annual Agatston Score progression predicted for the general population according to the Multi-Ethnic Study of Atherosclerosis (MESA) data in 57% of early RA patients. The significant increase of Agatston Score in accordance with Sevrukov’s method was met in one patient with newly diagnosed CAC and among patients with baseline CAC—in 29%. The presence of CAC progression was associated with lower baseline total cholesterol (TC) level (p < 0.05). The extent of CAC progression associated with male gender and arterial hypertension (AH) (p < 0.05). Association between CAC dynamic and statin therapy, RA activity and cumulative inflammatory burden, response to anti-rheumatic therapy and the type of this therapy were not detected. Early RA patients older than 45 years have high incidence of CAC progression during 18 months. More than half of the early RA patients had the increase in AS which exceeded the median annual progression of Agatston Score in the MESA. The CAC progression was associated with male gender, AH and lower baseline TC level. We did not detect any association between CAC progression and statin therapy, RA activity and type of anti-rheumatic therapy.
- 11 May 2018
- Published by Springer Nature in Rheumatology International
- Vol. 38 (7) , 1217-1224
Dynamic of changes in coronary artery calcification in early rheumatoid arthritis patients over 18 months
The coronary artery calcification (CAC) progression may be useful noninvasive predictor of future cardiovascular events (CVE). The progression rate of CAC in patients with early rheumatoid arthritis (RA) is poorly understood. To assess the dynamic of CAC scores in early RA patients for 18 months, 74 RA adult patients (ACR/EULAR criteria, 2010, duration ≤ 12 months, with moderate/high RA activity, without prior administration of disease-modifying anti-rheumatic drugs or glucocorticoids) were enrolled within the framework of the observational study: women 73%, median age 56 years, median RA duration 6 months, median DAS28[ESR] 5.4. Most of the patients had multiple Traditional Risk Factors (TRFs) of Cardiovascular Disease (CVD). All patients at baseline and after 18 months underwent 32-row scanning for CAC scoring. In patients younger than 45 years (n = 16) any CAC was not detected during 18 months. Among patients older than 45 years four new events of CAC were detected. Among patients older than 45 years with baseline CAC (n = 34) increase in CAC scores was detected in 82% cases. Among them, Δ Agatston Score exceeded the median annual Agatston Score progression predicted for the general population according to the Multi-Ethnic Study of Atherosclerosis (MESA) data in 57% of early RA patients. The significant increase of Agatston Score in accordance with Sevrukov’s method was met in one patient with newly diagnosed CAC and among patients with baseline CAC—in 29%. The presence of CAC progression was associated with lower baseline total cholesterol (TC) level (p < 0.05). The extent of CAC progression associated with male gender and arterial hypertension (AH) (p < 0.05). Association between CAC dynamic and statin therapy, RA activity and cumulative inflammatory burden, response to anti-rheumatic therapy and the type of this therapy were not detected. Early RA patients older than 45 years have high incidence of CAC progression during 18 months. More than half of the early RA patients had the increase in AS which exceeded the median annual progression of Agatston Score in the MESA. The CAC progression was associated with male gender, AH and lower baseline TC level. We did not detect any association between CAC progression and statin therapy, RA activity and type of anti-rheumatic therapy.
- Open Access
- 7 May 2018
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 56 (2) , 184-188-188
THE PREVALENCE OF TRADITIONAL CARDIOVASCULAR RISK FACTORS, SUBCLINICAL CAROTID ATHEROSCLEROSIS, CORONARY ARTERY CALCIFICATION IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS (A REMARCA STUDY
Сердечно-сосудистые осложнения (ССО) являются одной из самых распространенных причин смерти пациентов с псориатическим артритом (ПсА). Увеличение риска ССО при ПсА обусловлено сочетанием традиционных факторов риска (ТФР) сердечно-сосудистых заболеваний (ССЗ) и едиными иммуновоспалительными механизмами, лежащими в основе ПсА и атеросклероза. Цель исследования – оценить распространенность ТФР ССЗ, субклинического атеросклероза, коронарного кальциноза у молодых больных ранним периферическим ПсА. Материал и методы. В исследование включено 25 больных ранним ПсА (13 мужчин, 12 женщин), принимавших участие в исследовании РЕМАРКА. Медиана возраста – 36 [27; 46] лет, длительности ПсА – 5 [3; 7] мес, длительности ПС – 13 [9; 84] мес, DAS – 3,8 [3,4; 5,4]. Всем больным проведена оценка ТФР ССЗ, выполнена ультразвуковая допплерография (УЗДГ) сонных артерий (СА), оценка кальциноза коронарных артерий (ККА) с использованием мультиспиральной компьютерной томографии (МСКТ), эхокардографии (ЭхоКГ), суточное мониторирование артериального давления (СМАД). Результаты и обсуждение. У больных ранним ПсА выявлены следующие ТФР ССЗ: артериальная гипертензия – у 11 (44%), абдоминальное ожирение – у 14 (56%), курение – у 16 (64%), отягощенная наследственность по ССЗ – у 6 (24%), менопауза – у 5 (20%), дислипидемия – у 14 (56%) человек. Один ТФР у выявлен у 7 (28%), два – у 6 (24%), три – у 2 (8%), четыре – у 4 (16%), пять – у 6 (24%) человек. Сочетание трех и более ТФР ССЗ обнаружено у 12 (48%) пациентов. По результатам расчета десятилетнего суммарного коронарного риска (по шкале SCORE) к группе низкого риска отнесено 17 (68%), умеренного – 6 (24%), высокого – 1 (4%), очень высокого – 1 (4%) человек с острым нарушением мозгового кровообращения в анамнезе. Анализ связи между активностью ПсА и уровнем суммарного коронарного риска (по шкале SCORE) не выявил достоверных различий. Так, у пациентов с умеренной активностью ПсА низкий коронарный риск встречался в 7 (70%), умеренный – в 2 (20%), высокий – в 1 (10%) случае. У пациентов с высокой активностью ПсА низкий коронарный риск встречался в 10 (66,7%), умеренный – в 4 (26,6%), очень высокий риск – в 1 (6,7%) случае. При проведении УЗДГ СА атеросклеротические бляшки (АТБ) выявлены у 8 (32%), увеличение толщины комплекса интима–медиа (ТКИМ) >0,9 мм – также у 8 (32%) больных. По данным МСКТ, признаки ККА были у 4 (16%) пациентов. Обнаружена корреляция значений ТКИМ с уровнями липопротеидов низкой плотности (R=0,48; p=0,03), общего холестерина (R=0,53; p=0,01), систолическим артериальным давлением (R=0,59; p=0,02), наличием абдоминального ожирения (R=0,64; p=0,001); обратная связь между уровнем липопротеидов высокой плотности и С-реактивного белка (R=-0,52; p=0,03). Заключение. У молодых больных ПсА уже на ранней стадии заболевания отмечаются высокая распространенность ТФР ССЗ, атеросклеротические изменения СА и признаки ККА при относительно низких значениях суммарного коронарного риска по шкале SCORE, что может косвенно указывать на участие хронического воспаления в развитии атеросклероза.
- 7 May 2018
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 56 (2) , 184-188-188
Open AccessTHE PREVALENCE OF TRADITIONAL CARDIOVASCULAR RISK FACTORS, SUBCLINICAL CAROTID ATHEROSCLEROSIS, CORONARY ARTERY CALCIFICATION IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS (A REMARCA STUDY
Сердечно-сосудистые осложнения (ССО) являются одной из самых распространенных причин смерти пациентов с псориатическим артритом (ПсА). Увеличение риска ССО при ПсА обусловлено сочетанием традиционных факторов риска (ТФР) сердечно-сосудистых заболеваний (ССЗ) и едиными иммуновоспалительными механизмами, лежащими в основе ПсА и атеросклероза. Цель исследования – оценить распространенность ТФР ССЗ, субклинического атеросклероза, коронарного кальциноза у молодых больных ранним периферическим ПсА. Материал и методы. В исследование включено 25 больных ранним ПсА (13 мужчин, 12 женщин), принимавших участие в исследовании РЕМАРКА. Медиана возраста – 36 [27; 46] лет, длительности ПсА – 5 [3; 7] мес, длительности ПС – 13 [9; 84] мес, DAS – 3,8 [3,4; 5,4]. Всем больным проведена оценка ТФР ССЗ, выполнена ультразвуковая допплерография (УЗДГ) сонных артерий (СА), оценка кальциноза коронарных артерий (ККА) с использованием мультиспиральной компьютерной томографии (МСКТ), эхокардографии (ЭхоКГ), суточное мониторирование артериального давления (СМАД). Результаты и обсуждение. У больных ранним ПсА выявлены следующие ТФР ССЗ: артериальная гипертензия – у 11 (44%), абдоминальное ожирение – у 14 (56%), курение – у 16 (64%), отягощенная наследственность по ССЗ – у 6 (24%), менопауза – у 5 (20%), дислипидемия – у 14 (56%) человек. Один ТФР у выявлен у 7 (28%), два – у 6 (24%), три – у 2 (8%), четыре – у 4 (16%), пять – у 6 (24%) человек. Сочетание трех и более ТФР ССЗ обнаружено у 12 (48%) пациентов. По результатам расчета десятилетнего суммарного коронарного риска (по шкале SCORE) к группе низкого риска отнесено 17 (68%), умеренного – 6 (24%), высокого – 1 (4%), очень высокого – 1 (4%) человек с острым нарушением мозгового кровообращения в анамнезе. Анализ связи между активностью ПсА и уровнем суммарного коронарного риска (по шкале SCORE) не выявил достоверных различий. Так, у пациентов с умеренной активностью ПсА низкий коронарный риск встречался в 7 (70%), умеренный – в 2 (20%), высокий – в 1 (10%) случае. У пациентов с высокой активностью ПсА низкий коронарный риск встречался в 10 (66,7%), умеренный – в 4 (26,6%), очень высокий риск – в 1 (6,7%) случае. При проведении УЗДГ СА атеросклеротические бляшки (АТБ) выявлены у 8 (32%), увеличение толщины комплекса интима–медиа (ТКИМ) >0,9 мм – также у 8 (32%) больных. По данным МСКТ, признаки ККА были у 4 (16%) пациентов. Обнаружена корреляция значений ТКИМ с уровнями липопротеидов низкой плотности (R=0,48; p=0,03), общего холестерина (R=0,53; p=0,01), систолическим артериальным давлением (R=0,59; p=0,02), наличием абдоминального ожирения (R=0,64; p=0,001); обратная связь между уровнем липопротеидов высокой плотности и С-реактивного белка (R=-0,52; p=0,03). Заключение. У молодых больных ПсА уже на ранней стадии заболевания отмечаются высокая распространенность ТФР ССЗ, атеросклеротические изменения СА и признаки ККА при относительно низких значениях суммарного коронарного риска по шкале SCORE, что может косвенно указывать на участие хронического воспаления в развитии атеросклероза.
- 27 October 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (2) , 211-217
Calcification of coronary arteries in early rheumatoid arthritis prior to anti-rheumatic therapy
Accelerated coronary atherosclerosis is common in patients with rheumatoid arthritis (RA). To examine coronary artery calcification (CAC) frequency and severity, its correlation with traditional risk factors (TRF) of cardiovascular diseases (CVD) and inflammatory markers in patients with early RA prior to anti-rheumatic therapy. RA adult patients (ACR/EULAR criteria, 2010, duration ≤ 12 months, without prior administration of disease-modifying anti-rheumatic drugs, glucocorticoids) underwent 32-row scanning for CAC scoring. Agatston, volume and mass calcium scores were calculated. Additionally, we used calculators on the website of the Multi-Ethnic Study of Atherosclerosis. 74 RA patients (women n = 54 (73%), median age 56 years, median RA duration 6 months) with moderate/high RA activity (median DAS28 [ESR] 5.4) were enrolled within the framework of the observational study. Most of the patients had multiple TRFs of CVD and subclinical organ damage. CAC has been detected in 34 (46%) early RA patients. Calcification severity was significantly higher in men and in patients with ischemic heart disease (IHD). In patients younger than 45 years (n = 16) CAC was not detected. Among patients older than 45 years (n = 58), the frequency of CAC was 59%: asymptomatic patients—n = 46 (48%), IHD patients—n = 12 (100%). Among asymptomatic patients the presence of CAC associated with a significantly higher frequency of arterial hypertension (1.6 fold) compared with cases without CAC. Coronary age in asymptomatic patients with CAC and IHD patients was significantly greater than their actual age. More than half of early RA patients older 45 years had CAC. The presence and severity of CAC correlated positively with TRFs, but not with lipid levels and RA activity.
- 27 October 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (2) , 211-217
Calcification of coronary arteries in early rheumatoid arthritis prior to anti-rheumatic therapy
Accelerated coronary atherosclerosis is common in patients with rheumatoid arthritis (RA). To examine coronary artery calcification (CAC) frequency and severity, its correlation with traditional risk factors (TRF) of cardiovascular diseases (CVD) and inflammatory markers in patients with early RA prior to anti-rheumatic therapy. RA adult patients (ACR/EULAR criteria, 2010, duration ≤ 12 months, without prior administration of disease-modifying anti-rheumatic drugs, glucocorticoids) underwent 32-row scanning for CAC scoring. Agatston, volume and mass calcium scores were calculated. Additionally, we used calculators on the website of the Multi-Ethnic Study of Atherosclerosis. 74 RA patients (women n = 54 (73%), median age 56 years, median RA duration 6 months) with moderate/high RA activity (median DAS28 [ESR] 5.4) were enrolled within the framework of the observational study. Most of the patients had multiple TRFs of CVD and subclinical organ damage. CAC has been detected in 34 (46%) early RA patients. Calcification severity was significantly higher in men and in patients with ischemic heart disease (IHD). In patients younger than 45 years (n = 16) CAC was not detected. Among patients older than 45 years (n = 58), the frequency of CAC was 59%: asymptomatic patients—n = 46 (48%), IHD patients—n = 12 (100%). Among asymptomatic patients the presence of CAC associated with a significantly higher frequency of arterial hypertension (1.6 fold) compared with cases without CAC. Coronary age in asymptomatic patients with CAC and IHD patients was significantly greater than their actual age. More than half of early RA patients older 45 years had CAC. The presence and severity of CAC correlated positively with TRFs, but not with lipid levels and RA activity.
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e122-e123
Arterial stiffness in rheumatoid arthritis and coronary artery disease
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e122-e123
Arterial stiffness in rheumatoid arthritis and coronary artery disease